Twenty participants. That is the entire enrolled population of SLIM-1, and all 20 have now been successfully dosed, a milestone that sounds modest until you consider what Vivani Medical is actually attempting: a subdermal implant that deliv
Twenty participants.
That is the entire enrolled population of SLIM-1, and all 20 have now been successfully dosed, a milestone that sounds modest until you consider what Vivani Medical is actually attempting: a subdermal implant that delivers semaglutide continuously for months, eliminating the weekly injection regimen that underpins the entire commercial GLP-1 franchise.
The company filed an 8-K on August 6 confirming the dosing completion in its Phase 1 SLIM-1 trial, conducted in Australia under ethics approval granted as recently as June 25, 2026.
The design of SLIM-1 is deliberately lean.
It is open-label, randomized, and active-controlled, enrolling GLP-1 naïve adults who are overweight or obese, and it runs in Australia rather than the U.S., which speeds ethics review without bypassing rigorous oversight.
NPM-139 uses Vivani’s NanoPortal platform to create a miniature implant placed subdermally, releasing semaglutide at a controlled rate over an extended period.
The Phase 1 primary objectives center on pharmacokinetics, tolerability, and safety, the foundational data any developer needs before making a credible case to the FDA.
Completing enrollment and initial dosing simultaneously removes one operational risk and starts the pharmacokinetic clock for the entire cohort at roughly the same time, which tightens the comparative data window.
The clinical logic here is straightforward but the execution risk is real.
Wegovy received FDA approval in June 2021 as a once-weekly subcutaneous injection, and adherence to that regimen is a documented clinical problem, particularly over the multi-year treatment horizon that obesity medicine now demands.
An implant that maintains therapeutic semaglutide exposure without weekly dosing would address that gap directly.
But implant pharmacokinetics are notoriously difficult to optimize: achieving the exposure consistency of a controlled injection across diverse body compositions and implant sites is a formidable bioengineering challenge, and Phase 1 data will expose any variability quickly.
The single number to watch when SLIM-1 reports is coefficient of variation in semaglutide plasma concentration across the 20 participants.
High inter-subject variability would signal a reformulation problem that no Phase 2 design can paper over, while tight concentration distribution would validate the NanoPortal platform and justify advancing to efficacy-powered cohorts.
Source link: https://www.sec.gov/Archives/edgar/data/1266806/000175392626001349/vani-20260806.htm Jon Napitupulu + postsBio
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard.
Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
Jon Napitupulu FDA Clears IND for EOM613 Trial in Cancer Cachexia Patients Jon Napitupulu Zenas BioPharma Submits BLA for Obexelimab in IgG4-Related Disease Jon Napitupulu Senti Bio Advances SENTI-202 to Pivotal Trial With Donor X Selection Strategy Jon Napitupulu Lifestyle Program Improves Brain Health in Cognitive Decline Previous post Vistagen’s Fasedienol Phase 2 Data Due August 2026 for Social Anxiety Next post MetaVia’s DA-1726 Reaches Highest Doses in Phase 1 Study Ahead of 2026 Results You Might Also Like News FDA Approves Vepdegestrant for ESR1-Mutant Advanced Breast Cancer May 2, 2026 News New ENIGMAC Data Reveals Macrophage Role in Fibrotic Disease November 27, 2025 News ANI Pharma Publishes ‘New Day’ Ophthalmology Trial Results April 9, 2026
Peptides referenced: Semaglutide, GLP-1.
Related reading: Semaglutide: A New Treatment Option for AUD? What to Know, Peptide Research Enters New Era as High-Purity Demand Surges, States and the Federal Floor for Compounded GLP-1s and Peptides, Bank of America spends $250 million a year on weight loss drugs for staff: ‘We see a great impact.